BiotechTube

placebo of oseltamivir phosphate + oseltamivir phosphate + Banlangen (Radix Isatidis) granules + placebo of Banlangen(Radix Isatidis) granules

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Influenza

Conditions

Influenza

Trial Timeline

Apr 1, 2012 → Nov 1, 2016

NCT ID
NCT02232945

About placebo of oseltamivir phosphate + oseltamivir phosphate + Banlangen (Radix Isatidis) granules + placebo of Banlangen(Radix Isatidis) granules

placebo of oseltamivir phosphate + oseltamivir phosphate + Banlangen (Radix Isatidis) granules + placebo of Banlangen(Radix Isatidis) granules is a approved stage product being developed by Guangzhou Baiyunshan Pharmaceutical Holdings for Influenza. The current trial status is unknown. This product is registered under clinical trial identifier NCT02232945. Target conditions include Influenza.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02232945ApprovedUNKNOWN

Competing Products

20 competing products in Influenza

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
25
VaccineComac MedicalPhase 3
69
CT-P27 90 mg/kg + CT-P27 45 mg/kg + PlaceboCelltrionPhase 2
52
CT-P27 + PlaceboCelltrionPhase 2
52
CAIV-TPfizerPhase 3
76
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to OseltamivirShionogiPhase 3
77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to OseltamivirShionogiPhase 3
77
fH1 2 ug + fH1 8 ug + DSP-0546LP 2.5 ug + DSP-0546LP 5 ug + DSP-0546LP 10 ug + PlaceboSumitomo PharmaPhase 1
33
Monovalent Influenza VaccineAstraZenecaApproved
85
Monovalent Influenza VaccineAstraZenecaApproved
85
Trivalent Influenza VaccineAstraZenecaApproved
85
AZD4117 + AZD5315AstraZenecaPhase 1/2
41
Trivalent Influenza VaccineAstraZenecaApproved
85
FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)AstraZenecaApproved
85
Trivalent Influenza Virus VaccineAstraZenecaApproved
85
Comparator: Modified Process Vaccine + Comparator: COMVAX™MerckPhase 3
77
Molnupiravir + Placebo molnupiravir + Placebo oseltamivir + Oseltamivir + Influenza A VirusMerckPhase 1
33
V512 + Comparator: Placebo to V512MerckPhase 1
33
Vaxelis + PedvaxHIBMerckApproved
85

Other Products from Guangzhou Baiyunshan Pharmaceutical Holdings

Huatuo Zaizao PillsApproved
82
Fufangdanshen Tablets + PlaceboPhase 2
49